Print Page      Close Window

Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$13.41 + 0.06
Stock chart for: TOCA.O.  Currently trading at $13.41 with a 52 week high of $14.72 and a 52 week low of $10.25.
04/27/17 10:32 a.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option

04/19/17

Read More

Tocagen Announces Pricing of Initial Public Offering

04/13/17

Read More

Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia

03/16/17

Read More

Upcoming Events

View All  
There are currently no events scheduled.